+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epigenetics - Global Strategic Business Report

  • PDF Icon

    Report

  • 427 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1206797
The global market for Epigenetics was valued at US$1.7 Billion in 2023 and is projected to reach US$5.5 Billion by 2030, growing at a CAGR of 17.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Epigenetics Market - Key Trends & Drivers Summarized

What Is Epigenetics and Why Is It Transformative for Modern Medicine?

Epigenetics is the study of changes in gene expression that do not involve alterations to the underlying DNA sequence. These changes are influenced by environmental factors, lifestyle, and cellular signals and are mediated by mechanisms such as DNA methylation, histone modification, and non-coding RNA interactions. Epigenetics plays a crucial role in regulating biological processes, including development, aging, and disease progression, making it a transformative area of research and application in modern medicine.

The transformative potential of epigenetics lies in its ability to offer insights into how environmental factors and lifestyle choices affect gene expression and health outcomes. Epigenetic modifications are reversible, unlike genetic mutations, making them an attractive target for therapeutic intervention. For example, epigenetic therapies, such as histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors, are being developed to treat cancers, neurodegenerative disorders, and metabolic diseases. By understanding and targeting epigenetic mechanisms, researchers can develop personalized therapies that address the root causes of diseases, paving the way for precision medicine.

Additionally, epigenetics has a profound impact on diagnostics and drug development. Epigenetic biomarkers are increasingly being used to identify disease states, predict disease progression, and monitor treatment efficacy. These biomarkers, such as specific methylation patterns, enable early detection and non-invasive diagnostic methods for conditions like cancer. In drug development, epigenetic screening allows researchers to identify novel drug targets and optimize therapeutic strategies, accelerating innovation and improving patient outcomes. As a bridge between genetics and environment, epigenetics is central to advancing our understanding of health and disease and revolutionizing the future of medicine.

How Are Technological Advancements and Industry Demands Shaping the Epigenetics Market?

Technological advancements in sequencing, imaging, and computational tools are driving the epigenetics market by enabling more precise, high-throughput, and scalable research. Next-generation sequencing (NGS) technologies, such as whole-genome bisulfite sequencing and ChIP-sequencing, have revolutionized the study of epigenetics by allowing researchers to map DNA methylation and histone modifications across the genome. These tools provide unprecedented resolution and accuracy, enabling a deeper understanding of how epigenetic changes influence gene regulation and disease processes. Advances in single-cell sequencing further enhance these capabilities by allowing researchers to analyze epigenetic modifications at the single-cell level, uncovering cellular heterogeneity in tissues and tumors.

High-resolution imaging techniques, such as super-resolution microscopy and advanced fluorescence imaging, are also transforming epigenetics research by visualizing chromatin dynamics and histone modifications in real time. These tools allow scientists to study the spatial organization of epigenetic marks and their impact on gene expression within living cells, providing insights into the dynamic nature of epigenetic regulation. Combined with computational algorithms and AI-powered analytics, imaging and sequencing data can be integrated to generate comprehensive epigenetic maps, facilitating more accurate predictions of gene behavior and disease outcomes.

The increasing demand for personalized medicine is further shaping the epigenetics market as industries seek innovative ways to develop targeted therapies and diagnostics. Epigenetics provides a framework for understanding individual variations in gene expression and disease susceptibility, enabling the development of tailored interventions. For example, precision oncology leverages epigenetic biomarkers to identify tumor-specific modifications and guide treatment decisions. Similarly, epigenetic data informs the design of personalized lifestyle and nutritional recommendations, supporting preventive healthcare. Together, advancements in sequencing, imaging, and personalized medicine are driving the growth of the epigenetics market, making it a cornerstone of modern biomedical research and therapeutic innovation.

Where Is Epigenetics Making the Greatest Impact Across Industry Segments?

Epigenetics is making a significant impact across various industry segments, including oncology, neuroscience, regenerative medicine, and agriculture, each benefiting from enhanced understanding, diagnostics, and therapeutic approaches. In oncology, epigenetics is revolutionizing cancer research and treatment by uncovering the epigenetic mechanisms underlying tumor growth, metastasis, and resistance to therapy. Epigenetic therapies, such as HDAC inhibitors and DNA methyltransferase inhibitors, are being used to reactivate tumor suppressor genes and sensitize cancer cells to chemotherapy. Additionally, epigenetic biomarkers enable early cancer detection and personalized treatment strategies, improving patient outcomes and reducing the burden of disease.

In neuroscience, epigenetics is providing critical insights into the molecular mechanisms of neurodevelopmental and neurodegenerative disorders, such as Alzheimer’s disease, autism, and depression. Epigenetic modifications, including histone acetylation and DNA methylation, play a central role in brain plasticity and memory formation. By targeting these modifications, researchers are developing novel therapies to treat neurological conditions and restore cognitive function. Epigenetics also sheds light on the interplay between genetics and environmental factors in mental health, enabling the development of holistic approaches to prevention and treatment.

In regenerative medicine, epigenetics is driving advances in stem cell research and tissue engineering. Epigenetic reprogramming techniques, such as the induction of pluripotency, allow scientists to generate patient-specific stem cells for use in regenerative therapies. These stem cells can be differentiated into various cell types by modulating their epigenetic states, enabling the development of personalized treatments for conditions like diabetes, cardiovascular disease, and spinal cord injuries. Epigenetics also plays a role in enhancing the efficiency of tissue regeneration and improving the stability of engineered tissues, making it integral to the future of regenerative medicine.

In agriculture, epigenetics is being used to improve crop resilience, yield, and quality by understanding how plants respond to environmental stressors, such as drought, heat, and pathogens. Epigenetic modifications in plants regulate gene expression in response to changing conditions, enabling scientists to develop stress-tolerant crop varieties without genetic modification. These epigenetic approaches contribute to sustainable agriculture by reducing reliance on chemical inputs and enhancing food security in the face of climate change. Across these segments, epigenetics supports innovation, precision, and sustainability, highlighting its broad applications and transformative potential.

What Are the Key Drivers Fueling Growth in the Epigenetics Market?

The growth in the epigenetics market is driven by several key factors, including rising prevalence of chronic and complex diseases, increasing demand for personalized medicine, and advancements in research technologies. The rising prevalence of chronic diseases, such as cancer, cardiovascular conditions, and neurodegenerative disorders, is a primary driver as these conditions are often influenced by epigenetic modifications. Epigenetics provides insights into disease mechanisms and offers therapeutic targets for conditions with limited treatment options, driving investment in epigenetic research and drug development.

The increasing demand for personalized medicine is another significant driver, as healthcare shifts toward tailored approaches that address individual variations in disease susceptibility and response to treatment. Epigenetic biomarkers enable stratification of patient populations and guide the development of targeted therapies, particularly in oncology and rare genetic disorders. The ability to use epigenetic data to predict treatment efficacy and monitor disease progression enhances the precision and effectiveness of medical interventions, aligning with the broader trend of precision healthcare.

Advancements in research technologies, including next-generation sequencing, single-cell analysis, and bioinformatics, are also propelling the market. These technologies provide the tools needed to explore the complex and dynamic nature of epigenetic regulation, enabling breakthroughs in understanding and application. The integration of AI and machine learning further accelerates discoveries by identifying patterns and correlations in large epigenetic datasets. These technological advancements lower the cost and complexity of epigenetics research, making it more accessible to academic, clinical, and commercial entities.

Together, these drivers - disease prevalence, personalized medicine demand, and technological advancements - are fueling growth in the epigenetics market. As industries continue to leverage epigenetic insights to address unmet medical needs and innovate across sectors, epigenetics is poised to play a central role in shaping the future of healthcare, agriculture, and beyond.

Scope of the Study

The report analyzes the Epigenetics market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments:

Product (Epigenetics Kits, Epigenetics Reagents, Epigenetics Enzymes, Epigenetics Instruments & Consumables); Technology (DNA Methylation Technology, Histone Methylation Technology, Histone Acetylation Technology, Large Non-Coding RNA Technology, MicroRNA Modification Technology, Chromatin Structures Technology); Application (Oncology Application, Non-Oncology Application).

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Epigenetics Kits segment, which is expected to reach US$2.2 Billion by 2030 with a CAGR of a 18.9%. The Epigenetics Reagents segment is also set to grow at 18.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $641.1 Million in 2023, and China, forecasted to grow at an impressive 19.4% CAGR to reach $549.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abnova Corporation, Active Motif, Inc., biomodal Ltd., Bio-Rad Laboratories, Inc., BPS Bioscience, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Epigenetics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Epigenetics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Epigenetics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Some of the 95 major companies featured in this Epigenetics market report include:

  • Abnova Corporation
  • Active Motif, Inc.
  • biomodal Ltd.
  • Bio-Rad Laboratories, Inc.
  • BPS Bioscience, Inc.
  • Creative Biogene
  • Creative Diagnostics
  • EpiCypher, Inc.
  • Epigentek Group Inc.
  • Fios Genomics Ltd.
  • Genomescan
  • Illumina, Inc.
  • Merck Millipore
  • New England Biolabs, Inc.
  • Novogene Co. Ltd.
  • Pacific Biosciences of California, Inc.
  • Promega Corporation
  • Qiagen, Inc.
  • Revvity, Inc.
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Human Quest for Supremacy Over Diseases Sets the Tone for Growth of Epigenetics as a Transformative Force in Healthcare
EXHIBIT 1: Medical Research is Sacrosanct & So is Epigenetics’ Role as a Catalyst for Health Transformation: Global Pharmaceutical Research and Development Spending (In US$ Billion) for Years 2025, 2027, 2029, and 2031
Economic Frontiers: Trends, Trials & Transformations
EXHIBIT 2: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
EXHIBIT 3: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
EXHIBIT 4: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
Competition
EXHIBIT 5: Epigenetics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for 95 Players Worldwide in 2024 (E)
What is Epigenetics? A Technical Rumination
Influencer/Product/Technology Insights
Recent Market Activity
Innovations
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise in Chronic Diseases Sets the Stage for Growth of Epigenetics
EXHIBIT 6: As Disease Burden Rises So Does the Value of Epigenetics in Understanding Diseases & Developing Cutting Edge Therapies: Need for Medicines: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2024 and 2030
Growing Focus on Understanding Inflammatory Musculoskeletal Diseases Brings Epigenetics Into the Spotlight
EXHIBIT 7: Growing Burden of Musculoskeletal Disorders (MSDs) Pins Hope on Epigenetics for Solutions: Global Prevalence of MSDs (In Million) for Years 2024, 2030, 2040 and 2050
Exponential Rise in Cancer Pins Hope on Epigenetic Therapies
EXHIBIT 8: Rising Cancer Burden Exerts Pressure on Epigenetics to Move Swiftly from Laboratory Studies and Clinical Trials to Precision Medicine: Global Incidence of Cancer (In Million) for Years 2020, 2030 and 2040
The Shift Towards Personalized Medicine Expands The Role Of Epigenetics
EXHIBIT 9: As Personalized Medicine Gains Momentum, New Doors of Opportunities Open for Epigenome-Based Personalized Medicine: Global Market for Personalized Medicine (In US$ Billion) for Years 2025, 2027, 2029, 2031 and 2033
A New Era for Epigenetic Studies Open with the Entry of Artificial Intelligence
EXHIBIT 10: The Potential for Applying Artificial Intelligence to Epigenetics is Just Emerging Supported by Growing AI Spending: Global Spending on AI in Healthcare (In US$ Billion) for Years 2025, 2027, 2029, 2031, and 2033
Advancements in Epigenome Editing Drives Growth in the Market
Focus on Crop Improvement Amid Climate Change Drives Up the Value of Epigenetics in Agriculture
EXHIBIT 11: Inverse Relationship Between Rising Temperatures Due to Emissions Induced Climate Change & Crop Productivity Drives Interest in Epigenetics for Plant Breeding: Global CO2 Emissions (In Billion Metric Tons) for Years 1960, 1970, 1980, 1990, 2000, 2010, 2020, 2021, 2022, 2023 and 2024
Ethical Issues Continue to Surround the Field of Epigenetics
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Epigenetics Market Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 4: World 11-Year Perspective for Epigenetics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2019, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Epigenetics Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Epigenetics Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 7: World 11-Year Perspective for Epigenetics Kits by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Epigenetics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Epigenetics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 10: World 11-Year Perspective for Epigenetics Reagents by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Epigenetics Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Epigenetics Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 13: World 11-Year Perspective for Epigenetics Enzymes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Epigenetics Instruments & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Epigenetics Instruments & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 16: World 11-Year Perspective for Epigenetics Instruments & Consumables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for DNA Methylation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for DNA Methylation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 19: World 11-Year Perspective for DNA Methylation Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Histone Methylation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Histone Methylation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 22: World 11-Year Perspective for Histone Methylation Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Histone Acetylation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Histone Acetylation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 25: World 11-Year Perspective for Histone Acetylation Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Large Non-Coding RNA Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Large Non-Coding RNA Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 28: World 11-Year Perspective for Large Non-Coding RNA Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for MicroRNA Modification Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for MicroRNA Modification Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 31: World 11-Year Perspective for MicroRNA Modification Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Chromatin Structures Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Chromatin Structures Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 34: World 11-Year Perspective for Chromatin Structures Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 37: World 11-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Non-Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Non-Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2019 through 2022 and % CAGR
TABLE 40: World 11-Year Perspective for Non-Oncology Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2019, 2024 & 2030
III. MARKET ANALYSISUNITED STATESCANADAJAPANCHINAEUROPEFRANCEGERMANYITALYUNITED KINGDOMREST OF EUROPEASIA-PACIFICREST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abnova Corporation
  • Active Motif, Inc.
  • biomodal Ltd.
  • Bio-Rad Laboratories, Inc.
  • BPS Bioscience, Inc.
  • Creative Biogene
  • Creative Diagnostics
  • EpiCypher, Inc.
  • Epigentek Group Inc.
  • Fios Genomics Ltd.
  • Genomescan
  • Illumina, Inc.
  • Merck Millipore
  • New England Biolabs, Inc.
  • Novogene Co. Ltd.
  • Pacific Biosciences of California, Inc.
  • Promega Corporation
  • Qiagen, Inc.
  • Revvity, Inc.
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation

Table Information